5 Dividend Powerhouses Yielding Above 5% That Wall Street Still Backs

The article identifies five dividend stocks yielding more than 5% with Buy-leaning Wall Street consensus, led by Ares Capital at a 9.76% yield. ARCC's $0.48 quarterly dividend is supported by roughly $988 million of spillover income, though non-accruals increased to 2.4% and NAV fell to $19.35 from $19.94. Energy Transfer and Enterprise Products Partners also stand out, with ET raising FY2026 adjusted EBITDA guidance to $18.8-$19.1 billion after a 60% EPS beat, while EPD reported 1.9x distribution coverage.

Analysis

The apparent yield scarcity makes this basket trade more like a credit-duration complex than a conventional equity-income screen. The key differentiation is not headline coverage but sensitivity to the next macro turn: ARCC's floating-rate assets face net investment income pressure if policy easing continues, while rising non-accruals can force NAV marks and undermine the premium investors assign to its distribution. A high yield supported partly by spillover income is a cushion, not a permanent earnings substitute; the next quarterly portfolio-quality disclosure is the near-term catalyst.

Within midstream, EPD offers the cleanest balance-sheet and refinancing profile, whereas ET and MPLX embed more execution, leverage, and customer/concentration risk. ET's stronger recent momentum and bullish analyst skew leave less room for another upside surprise; any EBITDA-guide miss, acquisition financing, or widening high-yield spreads could drive a sharper de-rating than at EPD. Conversely, sustained commodity volatility can benefit fee and marketing franchises, but investors should separate recurring pipeline cash flow from episodic trading gains when assessing distribution safety.

BTI is the less-correlated candidate, but its rerating depends on modern oral products offsetting combustible declines fast enough to stabilize organic revenue rather than merely reduce the rate of contraction. The market may be underpricing buyback support and valuation optionality if reduced-risk products scale, while underpricing regulatory risk and currency translation. The article's analyst-consensus framing is low-information: consensus targets do not validate payout durability, particularly after strong year-to-date performance in the energy names.

Key Decisions for Investors

• Initiate a 3-6 month relative-value position: long EPD / short ET, sized dollar-neutral. Target 8-12% relative return from EPD's lower leverage and more defensive funding profile; exit if ET delivers two consecutive quarters of EBITDA growth above guidance without leverage expansion, or if the spread moves 10% against the position.
• Avoid adding ARCC ahead of its next portfolio-quality report; instead set an alert for non-accruals above 3.0% of amortized cost or NAV below $19/share. Either would challenge distribution-multiple support and create a potential 10-15% downside setup; stabilization in NAV and core earnings covering the regular dividend would invalidate the bearish watch.
• For diversified income exposure, prefer EPD over MPLX despite MPLX's higher stated yield. MPLX needs continued parent-refinery throughput and leverage discipline to justify its risk premium; revisit if leverage falls sustainably below 3.5x and third-party growth reduces MPC-linked concentration.
• Accumulate BTI only on a 7-10% pullback or following independently verified acceleration in reduced-risk product profitability, with a 6-12 month horizon. The risk/reward is favorable only if buybacks and oral-product mix can support multiple expansion; exit on a material cut to organic growth guidance or adverse U.S./European nicotine regulation.